Results 71 to 80 of about 66,314 (265)
Allergen-specific immunotherapy of Hymenoptera venom allergy:also a matter of diagnosis [PDF]
, 2015 Stings of hymenoptera can induce IgE-mediated hypersensitivity reactions in venom-allergic patients, ranging from local up to severe systemic reactions and even fatal anaphylaxis.
Schiener, Maximilian +4 more
core +2 more sources
Implementing PEN‐FAST for penicillin allergy delabeling in a high‐prevalence population
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.Summary Background and objectives Self‐reported penicillin allergies lead to the use of broad‐spectrum antibiotics, increase drug resistance, and constitute an economic burden. The PEN‐FAST score aims to identify low‐risk patients for direct drug provocation tests (DPT) without prior skin testing with a reported negative predictive value (NPV) of over ...
Deniz Göcebe +4 more
wiley +1 more source
Gastric biopsies with prominent eosinophils: Clinicopathologic features and response to therapy
Histopathology, EarlyView.The use of the term ‘histologic eosinophilic gastritis’ (EoG) has been proposed for cases with ≥30 eosinophils/high power field (HPF) in five separate HPF and with no known associated causes of eosinophilia; however, these criteria can miss cases with clinically significant eosinophilia and our study results argue against using this term for pathology ...
Nigar Anjuman Khurram +2 more
wiley +1 more source
Diagnosing Systemic Mastocytosis: State of the Art
International Journal of Laboratory Hematology, EarlyView.ABSTRACT With the advent of effective multikinase and selective tyrosine kinase inhibitors in systemic mastocytosis, diagnosing this rare disease has been critical to improving patient morbidity and mortality. This state‐of‐the‐art review interprets the international diagnostic criteria, including differences between the WHO 5th edition classification ...
Anton Rets, Tracy I. George
wiley +1 more source
Case Report: Treatment of systemic mastocytosis with sunitinib [version 1; referees: 2 approved]
F1000Research, 2017 Mast cell activation disease typically presents as chronic multisystem polymorbidity of generally inflammatory ± allergic theme. Presently, treatment of the rare, cytoproliferative variant systemic mastocytosis employs empirically selected therapies to ...
Gerhard J. Molderings +3 more
doaj +1 more source
Immunology, EarlyView.(A) Proposed model for Abl1 degradation via Nbeal2. Nbeal2 interacts with Abl1 with its WDR domain. This results in proteasomal degradation by a yet unidentified ubiquitin ligase. Therefore, Nbeal2 inactivation stabilises Abl1, which supports mast cell (MC) degeneration. (B) In wt MCs, the Abl1 protein level is controlled by Nbeal2. Furthermore, Nbeal2
Raphaela Marquardt +10 more
wiley +1 more source
Systemic Mastocytosis: Predominantly Involving the Bone, A Case Report [PDF]
Journal of Clinical and Diagnostic Research, 2013 Systemic mastocytosis (SM) is a rare clonal disorder of mast cells that can range from chronic smouldering type to aggressive mast cell leukaemia. It presents with non–specific symptoms like urticaria pigmentosa, unexplained flushing, hypotension and ...
Ketan P Mallya +4 more
doaj +1 more source
Experimental and clinical study of the efficacy of medicines containing omega-3 and 6 polyunsaturated fatty acids, in the treatment of inflammatory skin diseases [PDF]
, 2018 Over the recent years, the attention of scientists regarding the search for alternative means of treatment, including local therapy, of inflammatory skin diseases, has been focused in recent years on medicines containing omega-3 and 6 polyunsaturated ...
Grebennikova, S. V., Maklyakov, Y. S.
core +3 more sources
Omalizumab for Pediatric Cutaneous Mastocytosis: Case Report and Review
Pediatric Dermatology, EarlyView.ABSTRACT We report an 11‐month‐old boy with diffuse cutaneous mastocytosis whose severe pruritus and steroid dependence resolved following off‐label treatment with omalizumab. A literature review identified five additional pediatric cases in which omalizumab led to complete symptom resolution in an average of 2 months and permitted discontinuation of ...
Janis Chang +3 more
wiley +1 more source
Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis
Haematologica, 2011 Cooperating genetic events are likely to contribute to the phenotypic diversity of KIT-D816V systemic mastocytosis. In this study, 44 patients with KIT-D816V systemic mastocytosis were evaluated for coexisting NRAS, KRAS, HRAS or MRAS mutations ...
Todd M. Wilson +9 more
doaj +1 more source